NEW DRUGS Cometriq for Thyroid Cancer
ثبت نشده
چکیده
NEW DRUGS Cometriq for Thyroid Cancer Cabozantinib (Cometriq, Exelixis) has been approved with an orphan drug designation to treat metastatic medullary thyroid cancer (MTC). Cabozantinib blocks abnormal kinase proteins involved in the development and growth of medullary cancer cells. In a clinical study, treatment with cabozantinib increased progression-free survival and, in some patients, reduced the size of tumors. A boxed warning mentions the risk of severe and fatal bleeding. Perforated colon occurred in some patients. Another therapy for MTC, AstraZeneca’s vandetanib (Caprelsa, formerly Zactima), was approved in April 2011. Source: FDA, November 29, 2012
منابع مشابه
Thyroid and Parathyroid Cancers Overview
In November 2012, the US Food and Drug Administration (FDA) approved the tyrosine kinase inhibitor cabozantinib (Cometriq) for the treatment of metastatic medullary thyroid cancer. The EXAM trial, a 330-patient clinical trial that led to its approval, randomized patients in a 2:1 ratio to cabozantinib at 140 mg daily (n = 219) or to placebo (n = 111). The study found that cabozantinib increased...
متن کاملAssessment of thyroid cancer risk factors in Kurdistan province
ABSTRACT Background and Aim: Considering the increasing trend of thyroid cancer and increased number of new cases we performed this study to determine the risk factors for thyroid cancer in Kurdistan Province. Materials and Methods: 80 patients and 80 controls were matched and entered into this case-control study from September 2009 to September 2016 in Kurdistan Province. Data were colle...
متن کاملتغییرات ژنتیکی و اپیژنتیکی در سرطان تیرویید: مقاله مروری
Thyroid cancer is one of the most common endocrine malignancies and in the last two decades the number of involved people in the world has been increased. Thyroid cancer in Iran is the seventh most common cancer in women and 14th in men. In recent years many achievements regarding to molecular pathogenic factors such as the substantial role of signaling pathways and molecular abnormalities have...
متن کاملThyroid cancer cell lines: Critical models to study thyroid cancer biology and new therapeutic targets
Thyroid cancer is the most common endocrine malignancy and the incidence is rising. Currently, there are no effective treatments for patients with advanced forms of thyroid cancer. Anaplastic thyroid represents the most severe form of the disease with 95% mortality at 6 months. It is therefore critical to better understand the mechanisms involved in thyroid cancer development and progression in...
متن کاملNew perspectives on the treatment of differentiated thyroid cancer.
Even though differentiated thyroid carcinoma is a slow growing and usually curable disease, recurrence occurs in 20-40% and cellular dedifferentiation in up to 5% of cases. Conventional chemotherapy and radiotherapy have just a modest effect on advanced thyroid cancer. Therefore, dedifferentiated thyroid cancer represents a therapeutic dilemma and a critical area of research. Targeted therapy, ...
متن کامل